Burns Thomas William sold $42.6M of GKOS

Burns Thomas William (CHAIRMAN & CEO) sold 180,000 shares of GLAUKOS Corp (GKOS) at an average of $236.89 ($232.61–$245.90, $42.64M total) across 14 trades on 2026-11-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burns Thomas William
Published Nov 21, 2026, 12:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 12:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

This provides a concrete, time-stamped insider activity datapoint. Because it is explicitly under Rule 10b5-1, it is less likely to represent a fresh view on near-term fundamentals, but the large size can still influence short-term sentiment and positioning.

02

Market read

A large CEO sale is disclosed, but the 10b5-1 structure makes it more of a sentiment check than a fundamental catalyst.

03

What to watch

Traders may over-weight the dollar amount; the key is whether there are follow-on insider buys or additional filings after this sale window.

Relevance 6/10Novelty 6/10Timing: filed 2026-11-20, covering sales executed 2026-11-18

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos (GKOS), reporting CEO and Chairman Burns Thomas William’s open-market sale of shares under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Glaukos insider Form 4 shows CEO and Chairman Burns sold 180,000 shares in an open-market transaction worth about $42.64M under a 10b5-1 plan.

Expected impact

Likely limited near-term downside pressure as traders weigh the size of the sale against the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with clear transaction size and timing, but it is explicitly pre-arranged under Rule 10b5-1, which typically dampens interpretation of insider bearishness.

Market effects

Minimal sector read-through; this is company-specific insider liquidity rather than a sector catalyst.

No clear regional spillover beyond US small/mid-cap sentiment.

No direct global linkage indicated by the filing details.

Counterpoint

The sale could be routine diversification or tax planning, and the 10b5-1 plan suggests no new negative information.

Key entities

  • Glaukos Corp

    Subject of the Form 4 insider sale disclosure.

  • Burns Thomas William

    Chairman and CEO who sold 180,000 shares across 14 trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.